Pancreatic Cancer Research

ResearcherKagoshima UniversityActive in the last 2 years

Keita Wada

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112150955. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
77
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  2. A nomogram to preoperatively predict 1-year disease-specific survival in resected pancreatic cancer following neoadjuvant chemoradiation therapy. First author DOI 10.21147/j.issn.1000-9604.2020.01.12↗
  3. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk panc… Co-author DOI 10.1002/jhbp.601↗
  4. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Co-author DOI 10.1007/s00535-018-1506-7↗
  5. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  6. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcino… Co-author DOI 10.1002/jhbp.524↗
  7. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  8. Diffusion-weighted MR imaging of pancreatic cancer and inflammation: Prognostic significance of pancreatic inflammation in pancreatic cancer patients. Co-author DOI 10.1016/j.pan.2015.10.004↗
  9. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. Co-author DOI 10.1002/jhbp.274↗
  10. Screening for Pancreatic Cancer. Co-author DOI 10.1016/j.suc.2015.05.010↗
  11. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  12. Correlation of apparent diffusion coefficient measured by diffusion-weighted MRI and clinicopathologic features in pancreatic cancer patients. Co-author DOI 10.1007/s00534-011-0491-5↗
  13. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Co-author DOI 10.1007/s00534-013-0611-5↗
  14. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  15. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderlin… Co-author DOI 10.1097/mpa.0b013e3182056b1c↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 6 shared papers, 2011–2026 · strength 0.52
  2. Masayuki Sho · 5 shared papers, 2013–2026 · strength 0.49
  3. Ippei Matsumoto · 4 shared papers, 2014–2026 · strength 0.46
  4. Michiaki Unno · 4 shared papers, 2014–2026 · strength 0.46
  5. Fuyuhiko Motoi · 4 shared papers, 2014–2026 · strength 0.46
  6. Keiji Sano · 7 shared papers, 2013–2019 · strength 0.38
  7. Tomoo Kosuge · 3 shared papers, 2014–2026 · strength 0.37
  8. Hideki Ueno · 2 shared papers, 2019–2026 · strength 0.34
  9. Shinichiro Takahashi · 2 shared papers, 2013–2026 · strength 0.28
  10. Hirochika Toyama · 1 shared paper, 2026 · strength 0.25
  11. Hideyuki Yoshitomi · 1 shared paper, 2026 · strength 0.25
  12. Tsutomu Fujii · 1 shared paper, 2026 · strength 0.25
  13. Goro Honda · 3 shared papers, 2014–2019 · strength 0.21
  14. Sachiyo Kawamura · 2 shared papers, 2018–2019 · strength 0.18
  15. Hisae Iinuma · 2 shared papers, 2018–2019 · strength 0.18
  16. Kyoichi Takaori · 3 shared papers, 2013–2017 · strength 0.16
  17. Hiroki Yamaue · 3 shared papers, 2013–2019 · strength 0.15
  18. Junji Furuse · 2 shared papers, 2017–2019 · strength 0.13
  19. L. William Traverso · 2 shared papers, 2013–2015 · strength 0.12
  20. Tadahiro Takada · 3 shared papers, 2013–2015 · strength 0.11
  21. Yuichi Nagakawa · 1 shared paper, 2020 · strength 0.11
  22. Ho Kyoung Hwang · 1 shared paper, 2020 · strength 0.11
  23. Chang Moo Kang · 1 shared paper, 2020 · strength 0.11
  24. Dong Sup Yoon · 1 shared paper, 2020 · strength 0.11
  25. Woo Jung Lee · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.